Categories: CancerHealthcareNews

Galecto to Participate in Jefferies London Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming Jefferies London Healthcare Conference taking place on November 15-17, 2022. Details for the event are as follows:

Jefferies London Healthcare Conference
Date: Wednesday, November 16, 2022
Time: 7:25 am GMT
Webcast: Click Here

A live webcast of the presentation will be available on the “News & Events” section of Galecto’s Investor website at https://ir.galecto.com/news-and-events/events. A replay of the presentation will be available on this same website following the event.

About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate Phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

For more information, contact:

Galecto, Inc.  
Hans Schambye, CEO
Jon Freve, CFO
 
+45 70 70 52 10  
Investors/US Media/EU
Ashley R. Robinson
arr@lifesciadvisors.com
Sandya von der Weid
svonderweid@lifesciadvisors.com
+1 617 430 7577 +41 78 680 0538

Staff

Recent Posts

Therma Bright Announces Share Consolidation

Toronto, Ontario--(Newsfile Corp. - July 3, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)…

56 minutes ago

Sectra publishes Annual Report and Sustainability Report for 2024/2025

LINKÖPING, Sweden, July 3, 2025 /PRNewswire/ -- Medical imaging IT and cybersecurity company Sectra (STO: SECT B)…

2 hours ago

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech…

2 hours ago

CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for…

14 hours ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release…

14 hours ago

inTouch Addresses $6.7 Billion Senior Loneliness Crisis with Launch of AI Conversational Companion for North America

Complements Family Interactions & Supports Sandwich Generation of Caregivers with Daily Phone Calls to Seniors…

14 hours ago